Join the Chronic Rhinosinusitis with Nasal Polyps group to help and get support from people like you.
Chronic Rhinosinusitis with Nasal Polyps News
Related terms: CRSwNP
FDA Approves Omlyclo (omalizumab-igec), an Interchangeable Biosimilar to Xolair
JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ – Celltrion today announced the U.S. Food and Drug Administration (FDA) approved Omlyclo® (omalizumab-igec) as the first and only biosimilar designated a...
Baseline Characteristics ID Risk for Recurrent Endoscopic Sinus Surgery
THURSDAY, Feb. 6, 2025 -- A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery (ESS) among patients with chronic rhinosinusitis with nasal polyps (CRSwNP), acc...
Dupixent Approved in the US as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps
Paris and Tarrytown, N.Y. September 13, 2024. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17...
GSK Announces FDA Approval for Nucala (mepolizumab) for use in Adults with Chronic Rhinosinusitis with Nasal Polyps
29 July 2021 – GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as...
FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
PARIS and TARRYTOWN, N.Y., June 26, 2019 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for use with other medicines to treat chronic rhinosinusitis...